NovaBay Pharmaceuticals reported a net loss of $2.2 million, or $0.13 per share, in the first quarter of 2018 compared with a net loss of $4 million, or $0.26 per share, in the first quarter of 2017, according to a press release.
Net sales were $2.9 million compared with $3.7 million a year ago.
General and administrative costs decreased from $3.1 million last year to $1.6 million this year, which was attributed to lower stock-based compensation expense and lower professional services and consulting fees.
Research and development costs decreased from (Read more...)
Uncategorized